ATE358732T1 - Anti-virale vektoren - Google Patents
Anti-virale vektorenInfo
- Publication number
- ATE358732T1 ATE358732T1 AT99904956T AT99904956T ATE358732T1 AT E358732 T1 ATE358732 T1 AT E358732T1 AT 99904956 T AT99904956 T AT 99904956T AT 99904956 T AT99904956 T AT 99904956T AT E358732 T1 ATE358732 T1 AT E358732T1
- Authority
- AT
- Austria
- Prior art keywords
- viral
- nucleotide sequence
- encoding
- assembly
- particles
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 7
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 230000003612 virological effect Effects 0.000 abstract 7
- 239000002245 particle Substances 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 230000035897 transcription Effects 0.000 abstract 2
- 238000013518 transcription Methods 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9803351.7A GB9803351D0 (en) | 1998-02-17 | 1998-02-17 | Anti-viral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358732T1 true ATE358732T1 (de) | 2007-04-15 |
Family
ID=10827139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99904956T ATE358732T1 (de) | 1998-02-17 | 1999-02-17 | Anti-virale vektoren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6541248B1 (de) |
| EP (2) | EP1054988B1 (de) |
| JP (1) | JP2002503477A (de) |
| CN (1) | CN1297486A (de) |
| AT (1) | ATE358732T1 (de) |
| AU (1) | AU757284B2 (de) |
| CA (1) | CA2321097A1 (de) |
| DE (1) | DE69935714T2 (de) |
| GB (1) | GB9803351D0 (de) |
| WO (1) | WO1999041397A1 (de) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2221600A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| EP1535995A1 (de) * | 1998-12-31 | 2005-06-01 | Chiron Corporation | Polynukleotide kodierend für Antigene des HIV Type C ENV Polypeptids, und Verwendungen davon |
| JP2003523721A (ja) * | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| AP1674A (en) * | 1999-11-16 | 2006-10-30 | Geneart Ag | The genome of the HIV-1 inter-subtype (C/B') and use thereof. |
| WO2001068836A2 (en) * | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP2020450B9 (de) * | 2000-09-01 | 2011-09-14 | Gen-Probe Incorporated | HIV-1-Sequenzverstärkung zur Erkennung von Sequenzen in Zusammenhang mit Wirkstoffresistenz-Mutationen |
| JP2004508064A (ja) * | 2000-09-15 | 2004-03-18 | メルク エンド カムパニー インコーポレーテッド | コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン |
| NZ525283A (en) * | 2000-09-22 | 2008-06-30 | Virxsys Corp | Conditionally replicating vectors, methods for their production and use |
| GB0024550D0 (de) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| IL157087A0 (en) | 2001-01-25 | 2004-02-08 | Virxsys Corp | A method for identifying a function of a gene sequence |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| CA2452015C (en) | 2001-07-05 | 2012-07-03 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US6835568B2 (en) | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
| EP1504108B1 (de) | 2002-02-01 | 2013-04-17 | Oxford Biomedica (UK) Limited | Lentiviraler Vektor |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| US8765462B2 (en) | 2007-05-04 | 2014-07-01 | University Health Network | IL-12 immunotherapy for cancer |
| US20090088625A1 (en) * | 2007-10-01 | 2009-04-02 | Kenneth Oosting | Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery |
| DK3192874T3 (da) | 2008-06-18 | 2019-12-16 | Oxford Biomedica Ltd | Virusoprensning |
| WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
| WO2014093965A1 (en) | 2012-12-14 | 2014-06-19 | Case Western Reserve University | Genomic rna packaging enhancer element |
| GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| RU2745705C2 (ru) | 2014-09-15 | 2021-03-30 | МОЛМЕД СпА | Химерные рецепторы антигенов |
| GB201418965D0 (de) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| JP6842417B2 (ja) | 2014-12-16 | 2021-03-17 | シー３ジェイ セラピューティクス インコーポレイテッド | インビトロウイルスゲノム工学のための組成物及びその方法 |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CN116334143A (zh) | 2015-11-23 | 2023-06-27 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
| US20190017096A1 (en) | 2016-03-10 | 2019-01-17 | Nightstarx Limited | Prenylation assay |
| EP3318285A1 (de) | 2016-11-08 | 2018-05-09 | Oxford University Innovation Limited | Behandlung von augenerkrankungen |
| EP3548618A1 (de) | 2016-12-01 | 2019-10-09 | Nestec S.A. | Verfahren zur modulation von fam46a |
| EP3375876A1 (de) | 2017-03-13 | 2018-09-19 | Evonetix Ltd | Verfahren zur herstellung von dobbeltsträngigen polynukleotiden basierend auf oligonukleotiden mit ausgewählten und unterschiedlichen schmelztemperaturen |
| US20210189389A1 (en) | 2017-03-31 | 2021-06-24 | Societe Des Produits Nestle S.A. | Methods of modulating ank1 |
| CA3060145A1 (en) | 2017-04-21 | 2018-10-25 | Ospedale San Raffaele S.R.L. | Cytyokine gene therapy for treating or preventing cancer |
| US11597755B2 (en) | 2017-04-24 | 2023-03-07 | Ospedale San Raffaele S.R.L. | TCR and peptides |
| WO2019068854A1 (en) | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
| CN112041458A (zh) | 2017-10-17 | 2020-12-04 | 夜星有限公司 | 异戊烯化测定法 |
| CA3083042A1 (en) | 2017-11-21 | 2019-05-31 | Societe Des Produits Nestle S.A. | Methods of modulating alk |
| EP3696272A1 (de) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviraler vektor |
| WO2019134866A1 (en) | 2018-01-03 | 2019-07-11 | Molmed Spa | Chimeric antigen receptors containing optimal spacer region |
| CN112367973A (zh) | 2018-05-15 | 2021-02-12 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| CN112088216A (zh) | 2018-05-17 | 2020-12-15 | 雀巢产品有限公司 | 调节nkx6.3的方法 |
| CA3102055A1 (en) | 2018-05-30 | 2019-12-05 | Glycostem Therapeutics B.V. | Car nk cells |
| AU2019301053A1 (en) | 2018-07-09 | 2021-01-28 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| CA3120282A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| JP2022507454A (ja) | 2018-11-14 | 2022-01-18 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | Ｃｎｓ送達のためのフソソーム組成物 |
| GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
| CA3124039A1 (en) | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| AU2020236735A1 (en) | 2019-03-10 | 2021-10-14 | Oxford Biomedica (Uk) Limited | Gene therapy compositions and methods for treating parkinson's disease |
| GB201905301D0 (en) | 2019-04-15 | 2019-05-29 | Ospedale San Raffaele Srl | Gene therapy |
| GB201907493D0 (en) | 2019-05-28 | 2019-07-10 | Ospedale San Raffaele | Agents and methods for treating viral infections |
| GB201912515D0 (en) | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| CA3152525A1 (en) | 2019-09-03 | 2021-03-11 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| CN114667161A (zh) | 2019-11-12 | 2022-06-24 | 牛津生物医学（英国）有限公司 | 生产系统 |
| JP2023513303A (ja) | 2020-02-13 | 2023-03-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | レンチウイルスベクターの製造 |
| US20230138428A1 (en) | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| KR20220154734A (ko) | 2020-03-13 | 2022-11-22 | 옥스포드 바이오메디카(유케이) 리미티드 | 렌티바이러스 벡터 |
| WO2021202604A1 (en) | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
| BR112022021918A2 (pt) | 2020-04-27 | 2023-03-14 | Univ Iowa Res Found | Composições e métodos para o tratamento de fibrose cística |
| GB202007169D0 (en) | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| EP4204447A1 (de) | 2020-08-28 | 2023-07-05 | Sana Biotechnology, Inc. | Modifizierte antivirale bindemittel |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| GB202018657D0 (en) | 2020-11-26 | 2021-01-13 | Ospedale San Raffaele Srl | Agents and methods for increasing liver immune response |
| EP4267601A1 (de) | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Induzierbares signalprotein |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| WO2022162247A1 (en) | 2021-02-01 | 2022-08-04 | Epsilen Bio S.R.L. | Gene silencing |
| JP2024506208A (ja) | 2021-02-15 | 2024-02-09 | オスペダーレ サン ラファエレ エス．アール．エル | 癌の治療のためのエピジェネティックサイレンシング |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| KR20240005950A (ko) | 2021-05-12 | 2024-01-12 | 폰다지오네 텔레톤 이티에스 | 벡터 시스템 |
| WO2022251712A1 (en) | 2021-05-28 | 2022-12-01 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| WO2023064860A1 (en) * | 2021-10-13 | 2023-04-20 | The Cleveland Clinic Foundation | Mrna vaccine design via the alteration of codon usage |
| WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| TW202334398A (zh) | 2021-12-22 | 2023-09-01 | 英商圭爾醫療有限公司 | 組成型細胞激素受體 |
| EP4209511A1 (de) | 2022-01-05 | 2023-07-12 | Gyala Therapeutics Sociedad Limitada | Anti-cd84-antikörper amd chimäre antigenrezeptoren |
| WO2023131657A1 (en) | 2022-01-05 | 2023-07-13 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies and chimeric antigen receptors |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| EP4269426A1 (de) | 2022-04-29 | 2023-11-01 | Ospedale San Raffaele S.r.l. | Gentherapie |
| WO2024008950A1 (en) | 2022-07-08 | 2024-01-11 | Ospedale San Raffaele S.R.L. | Transgene cassettes |
| EP4303226A1 (de) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgen-kassetten und epigenetische schalldämpfer zur behandlung von störungen |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024033544A1 (en) | 2022-08-12 | 2024-02-15 | Ospedale San Raffaele S.R.L. | Deglycosylation of native glycoproteins expressed on a tumor cell surface |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0301293B2 (de) | 1987-07-29 | 1995-08-30 | BASF Lacke + Farben AG | Kathodisch abscheidbare Kunstharze enthaltende wässrige Elektrotauchlackbäder und Verfahren zur Beschichtung elektrisch leitfähiger Substrate |
| WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
| IL108719A0 (en) * | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| WO1995030755A1 (fr) * | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| WO1996037781A1 (fr) * | 1995-05-26 | 1996-11-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Methode de dosage d'anticorps inhibant l'activite de la transcriptase inverse |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1380650B1 (de) * | 1995-11-28 | 2010-01-20 | The Johns Hopkins University School Of Medicine | Konditionell replizierende virale Vektoren und ihre Verwendung |
| GB9525639D0 (en) | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
| AU729934B2 (en) | 1996-01-23 | 2001-02-15 | Oxford Biomedica (Uk) Limited | Retroviral vector and its use in gene therapy |
| KR19990087126A (ko) | 1996-02-22 | 1999-12-15 | 폴락 돈나 엘. | 합성 사람 면역결핍 바이러스 유전자 |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| NZ334860A (en) | 1996-10-17 | 2001-02-23 | Oxford Biomedica Ltd | Retroviral vectors with one or more auxiliary genes vpr, vif, tat and nef to be absent; with evidence that if all auxiliary genes absent the transduction efficiency is greatest |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| ATE342916T1 (de) * | 1997-02-07 | 2006-11-15 | Merck & Co Inc | Synthetische hiv gag gene |
| US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
| DE69829471T2 (de) * | 1997-05-13 | 2006-04-13 | University Of North Carolina At Chapel Hill | Auf lentivirus basierende gentransfer-vektoren |
| CN1322137C (zh) | 1997-12-22 | 2007-06-20 | 牛津生物医学（英国）有限公司 | 基于马传染性贫血病毒(eiav)的逆转录病毒载体 |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6958226B1 (en) * | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| AU6139699A (en) | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| GB9825524D0 (en) | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| IL146090A0 (en) | 1999-04-26 | 2002-07-25 | Leuven K U Res & Dev | A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells |
| GB9923558D0 (en) | 1999-10-05 | 1999-12-08 | Oxford Biomedica Ltd | Producer cell |
-
1998
- 1998-02-17 GB GBGB9803351.7A patent/GB9803351D0/en not_active Ceased
-
1999
- 1999-02-17 CA CA002321097A patent/CA2321097A1/en not_active Abandoned
- 1999-02-17 AT AT99904956T patent/ATE358732T1/de not_active IP Right Cessation
- 1999-02-17 WO PCT/GB1999/000325 patent/WO1999041397A1/en active IP Right Grant
- 1999-02-17 AU AU25274/99A patent/AU757284B2/en not_active Expired
- 1999-02-17 CN CN99805126A patent/CN1297486A/zh active Pending
- 1999-02-17 JP JP2000531578A patent/JP2002503477A/ja not_active Ceased
- 1999-02-17 EP EP99904956A patent/EP1054988B1/de not_active Expired - Lifetime
- 1999-02-17 DE DE69935714T patent/DE69935714T2/de not_active Expired - Lifetime
- 1999-02-17 EP EP07000193A patent/EP1790658A3/de not_active Withdrawn
-
2000
- 2000-04-20 US US09/552,950 patent/US6541248B1/en not_active Expired - Lifetime
-
2003
- 2003-01-27 US US10/351,938 patent/US7790419B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6541248B1 (en) | 2003-04-01 |
| CA2321097A1 (en) | 1999-08-19 |
| AU2527499A (en) | 1999-08-30 |
| US7790419B2 (en) | 2010-09-07 |
| DE69935714T2 (de) | 2007-12-27 |
| EP1790658A3 (de) | 2007-09-12 |
| EP1054988A1 (de) | 2000-11-29 |
| US20040009603A1 (en) | 2004-01-15 |
| JP2002503477A (ja) | 2002-02-05 |
| AU757284B2 (en) | 2003-02-13 |
| EP1790658A2 (de) | 2007-05-30 |
| CN1297486A (zh) | 2001-05-30 |
| WO1999041397A1 (en) | 1999-08-19 |
| GB9803351D0 (en) | 1998-04-15 |
| EP1054988B1 (de) | 2007-04-04 |
| DE69935714D1 (de) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935714D1 (de) | Anti-virale vektoren | |
| GB2363794A (en) | Anti-viral vectors | |
| ATE330007T1 (de) | Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen | |
| DK1895010T3 (da) | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) | |
| ATE470704T1 (de) | Rekombinantes sendai-virus | |
| DE69833652D1 (de) | System zum exprimieren einer hyperthermostabilen protease | |
| NZ319786A (en) | HCV NS3 protein fragments with helicase activity and improved solubility | |
| AU8700291A (en) | Hcv-specific peptides, agents therefor and the use thereof | |
| EP0710288A4 (de) | Adenovirale vektoren für die behandlung der hämophilie | |
| ATE284954T1 (de) | Hyaluronan synthase gen und seine verwendung | |
| DK0842279T3 (da) | Hjælpevirus til fremstilling af rekombinante virusvektorer | |
| AU2197392A (en) | Hepatitis C virus from C-100-3 and env/core regions | |
| AU6839898A (en) | Vaccine composition for preventing or treating c hepatitis | |
| DE60237791D1 (de) | Zytokinproteinfamilie | |
| DE69230984T4 (de) | Verwendung einer Herpesprotease | |
| DE69034052T2 (de) | Rekombinante vectoren , die für selbstzusammengesetzte, defekte, sich nichtselbstvermehrende viruspartikel kodieren | |
| DE59109072D1 (de) | Klonierung der N-Methylhydantoinase | |
| DK0627004T3 (da) | Forbedringer ved eller i forbindelse med malariavaccine | |
| WO1999057284A3 (en) | Attenuated influenza viruses | |
| WO2001059108A3 (en) | Inhibitors of apoptosis | |
| DK0828004T3 (da) | Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær | |
| AU2002349094A1 (en) | Hdv nucleic acid molecules, fragments and applications thereof | |
| ES2133275T3 (es) | N-carbamoil-sarcosina-amidohidrolasa clonada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |